The Ministry of Health has issued an ordinance which provides for the inclusion of the drug Risdiplam in the Unified Health System (SUS). It is used for the treatment of spinal muscular atrophy (SMA) type 1.
Rare, SMA is a genetic disease that interferes with the body’s ability to produce a protein essential for the survival of motor neurons, which provide muscle control and strength. The disease is degenerative and incurable.
The order of the Ministry of Health also provides that the drug must be offered in the SUS, within 180 days.
Click here to learn how to tune in to TV Brasil programming.